Tovetumab

Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC) [1][2].

Product Specifications

CAS Number

[1243266-04-7]

Product Name Alternative

MEDI-575

UNSPSC

12352203

Target

PDGFR

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tovetumab.html

Purity

99.49

Solubility

10 mM in DMSO

Smiles

[Tovetumab]

Molecular Weight

(145.39 kDa)

References & Citations

[1]Meina Liang, et al. A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy. AAPS J. 2020 Nov 18;23 (1) :4. |[2]Naomi Laing, et al. Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer. Mol Pharmacol. 2013 Jun;83 (6) :1247-56.